&w=1200&q=75)
&w=1200&q=75)
Investigation Launched into InMed Pharmaceuticals' Merger Deal
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of InMed Pharmaceuticals, Inc. (NASDAQ: INM)
Image: Benzinga
Monteverde & Associates PC is investigating InMed Pharmaceuticals, Inc. (NASDAQ: INM) regarding its merger with Mentari Therapeutics, Inc. Shareholders are expected to own about 1.51% of the new entity post-merger. Concerns have been raised about the fairness of this deal.
- 01InMed Pharmaceuticals shareholders will hold approximately 1.51% of the combined company after the merger with Mentari Therapeutics.
- 02Juan Monteverde, a class action attorney, leads the investigation and has a history of recovering millions for shareholders.
- 03Monteverde & Associates PC is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
- 04The firm operates from the Empire State Building in New York City and has a national presence in class action litigation.
- 05Potential clients can contact the firm for free consultations regarding their rights as shareholders.
Advertisement
In-Article Ad
Monteverde & Associates PC, a prominent class action law firm based in New York City, has initiated an investigation into InMed Pharmaceuticals, Inc. (NASDAQ: INM) concerning its proposed merger with Mentari Therapeutics, Inc. Following the merger, InMed shareholders are projected to own around 1.51% of the newly formed entity. The firm aims to assess whether this arrangement is fair to shareholders. Attorney Juan Monteverde, who leads the investigation, has successfully recovered millions for clients in the past and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. Monteverde & Associates PC operates nationally and is known for its successful track record in securities litigation, including cases that have reached the U.S. Supreme Court. Shareholders concerned about their rights or the merger's implications are encouraged to reach out to the firm for a free consultation.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
Do you think shareholders should challenge the merger between InMed Pharmaceuticals and Mentari Therapeutics?
Connecting to poll...
Read the original article
Visit the source for the complete story.